EP1483280A4 - Fluorescent nitrogenous base and nucleosides incorporating same - Google Patents
Fluorescent nitrogenous base and nucleosides incorporating sameInfo
- Publication number
- EP1483280A4 EP1483280A4 EP03744226A EP03744226A EP1483280A4 EP 1483280 A4 EP1483280 A4 EP 1483280A4 EP 03744226 A EP03744226 A EP 03744226A EP 03744226 A EP03744226 A EP 03744226A EP 1483280 A4 EP1483280 A4 EP 1483280A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- fluorescent
- nitrogenous base
- incorporating same
- nucleosides incorporating
- nucleosides
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 title 1
- 239000002777 nucleoside Substances 0.000 title 1
- 125000003835 nucleoside group Chemical group 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/14—Pyrrolo-pyrimidine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/23—Heterocyclic radicals containing two or more heterocyclic rings condensed among themselves or condensed with a common carbocyclic ring system, not provided for in groups C07H19/14 - C07H19/22
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Saccharide Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36244802P | 2002-03-08 | 2002-03-08 | |
| US362448P | 2002-03-08 | ||
| PCT/US2003/006946 WO2003077215A2 (en) | 2002-03-08 | 2003-03-06 | Fluorescent nitrogenous base and nucleosides incorporating same |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| EP1483280A2 EP1483280A2 (en) | 2004-12-08 |
| EP1483280A4 true EP1483280A4 (en) | 2007-05-02 |
| EP1483280B1 EP1483280B1 (en) | 2012-10-24 |
Family
ID=27805176
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP03744226A Expired - Lifetime EP1483280B1 (en) | 2002-03-08 | 2003-03-06 | Fluorescent nitrogenous base and nucleosides incorporating same |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US7144995B2 (en) |
| EP (1) | EP1483280B1 (en) |
| AU (1) | AU2003225701A1 (en) |
| WO (1) | WO2003077215A2 (en) |
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2512484A1 (en) * | 2003-01-16 | 2004-05-08 | Hybridon, Inc. | Modulation of immunostimulatory properties of oligonucleotide-based compounds by utilizing modified immunostimulatory dinucleotides |
| US7851152B2 (en) * | 2004-09-25 | 2010-12-14 | Yaodong Chen | Fluorescent base analogues' usage in the characterization of nucleic acid molecules and their interactions |
| JP5713377B2 (en) | 2005-12-28 | 2015-05-07 | ザ スクリプス リサーチ インスティテュート | Natural antisense and non-coding RNA transcripts as drug targets |
| WO2008082440A2 (en) * | 2006-08-25 | 2008-07-10 | Emory University | Fluorescent nucleoside analogues |
| CN102239260B (en) | 2008-10-03 | 2017-04-12 | 库尔纳公司 | Treatment of apolipoprotein-a1 related diseases by inhibition of natural antisense transcript to apolipoprotein-a1 |
| US20110294870A1 (en) | 2008-12-04 | 2011-12-01 | Opko Curna, Llc | Treatment of tumor suppressor gene related diseases by inhibition of natural antisense transcript to the gene |
| ES2629630T3 (en) | 2008-12-04 | 2017-08-11 | Curna, Inc. | Treatment of diseases related to erythropoietin (EPO) by inhibiting the natural antisense transcript to EPO |
| ES2600781T3 (en) | 2008-12-04 | 2017-02-10 | Curna, Inc. | Treatment for diseases related to vascular endothelial growth factor (vegf) by inhibiting natural antisense transcripts of vegf |
| ES2762610T3 (en) | 2009-02-12 | 2020-05-25 | Curna Inc | Treatment of diseases related to brain-derived neurotrophic factor (BDNF) by inhibition of natural antisense transcript for BDNF |
| CN102482677B (en) | 2009-03-16 | 2017-10-17 | 库尔纳公司 | Treatment of nuclear factor (erythroid-derived 2)-like 2 (NRF2)-associated diseases by inhibiting the natural antisense transcript of NRF2 |
| WO2010107740A2 (en) | 2009-03-17 | 2010-09-23 | Curna, Inc. | Treatment of delta-like 1 homolog (dlk1) related diseases by inhibition of natural antisense transcript to dlk1 |
| ES2609655T3 (en) | 2009-05-06 | 2017-04-21 | Curna, Inc. | Treatment of diseases related to tristetraproline (TTP) by inhibition of natural antisense transcript for TTP |
| CN103223177B (en) | 2009-05-06 | 2016-08-10 | 库尔纳公司 | By suppression therapy lipid transfer and the metabolic gene relevant disease of the natural antisense transcript for lipid transfer and metabolic gene |
| JP5931720B2 (en) | 2009-05-08 | 2016-06-08 | クルナ・インコーポレーテッド | Treatment of dystrophin family-related diseases by suppression of natural antisense transcripts on the DMD family |
| DK2432881T3 (en) | 2009-05-18 | 2018-02-26 | Curna Inc | TREATMENT OF REPROGRAMMING FACTOR-RELATED DISEASES BY INHIBITING NATURAL ANTISENSE TRANSCRIPTS TO A REPROGRAMMING FACTOR |
| CA2762987A1 (en) | 2009-05-22 | 2010-11-25 | Joseph Collard | Treatment of transcription factor e3 (tfe3) and insulin receptor substrate 2 (irs2) related diseases by inhibition of natural antisense transcript to tfe3 |
| KR101704988B1 (en) | 2009-05-28 | 2017-02-08 | 큐알엔에이, 인크. | Treatment of antiviral gene related diseases by inhibition of natural antisense transcript to an antiviral gene |
| WO2010148050A2 (en) | 2009-06-16 | 2010-12-23 | Curna, Inc. | Treatment of collagen gene related diseases by inhibition of natural antisense transcript to a collagen gene |
| US8951981B2 (en) | 2009-06-16 | 2015-02-10 | Curna, Inc. | Treatment of paraoxonase 1 (PON1) related diseases by inhibition of natural antisense transcript to PON1 |
| WO2010151671A2 (en) | 2009-06-24 | 2010-12-29 | Curna, Inc. | Treatment of tumor necrosis factor receptor 2 (tnfr2) related diseases by inhibition of natural antisense transcript to tnfr2 |
| EP2446037B1 (en) | 2009-06-26 | 2016-04-20 | CuRNA, Inc. | Treatment of down syndrome gene related diseases by inhibition of natural antisense transcript to a down syndrome gene |
| CN102712925B (en) | 2009-07-24 | 2017-10-27 | 库尔纳公司 | Treatment of SIRTUIN (SIRT)-associated diseases by inhibiting the natural antisense transcript of SIRTUIN (SIRT) |
| CN102762731B (en) | 2009-08-05 | 2018-06-22 | 库尔纳公司 | By inhibiting to treat insulin gene (INS) relevant disease for the natural antisense transcript of insulin gene (INS) |
| CN104313027B (en) | 2009-08-11 | 2018-11-20 | 库尔纳公司 | By inhibiting the natural antisense transcript of adiponectin (ADIPOQ) to treat adiponectin (ADIPOQ) related disease |
| KR101805213B1 (en) | 2009-08-21 | 2017-12-06 | 큐알엔에이, 인크. | Treatment of 'c terminus of hsp70-interacting protein' (chip) related diseases by inhibition of natural antisense transcript to chip |
| CA2771172C (en) | 2009-08-25 | 2021-11-30 | Opko Curna, Llc | Treatment of 'iq motif containing gtpase activating protein' (iqgap) related diseases by inhibition of natural antisense transcript to iqgap |
| US20120295952A1 (en) | 2009-09-25 | 2012-11-22 | Curna, Inc. | Treatment of filaggrin (flg) related diseases by modulation of flg expression and activity |
| US8394948B2 (en) * | 2009-09-30 | 2013-03-12 | Glen Research Corporation | Reagents utilizing a serinol scaffold for labeling synthetic oligonucleotides |
| JP6025567B2 (en) | 2009-12-16 | 2016-11-16 | カッパーアールエヌエー，インコーポレイテッド | Treatment of MBTPS1-related diseases by inhibition of the natural antisense transcript against the membrane-bound transcription factor peptidase, site 1 (MBTPS1) |
| CN102869776B (en) | 2009-12-23 | 2017-06-23 | 库尔纳公司 | HGF relevant diseases are treated by suppressing the natural antisense transcript of HGF (HGF) |
| RU2619185C2 (en) | 2009-12-23 | 2017-05-12 | Курна, Инк. | Treatment of diseases associated with uncoupling proteins 2 (ucp2), by inhibiting of natural antisense transcript to ucp2 |
| ES2585829T3 (en) | 2009-12-29 | 2016-10-10 | Curna, Inc. | Treatment of diseases related to tumor protein 63 (p63) by inhibition of natural antisense transcription to p63 |
| EP2519633B1 (en) | 2009-12-29 | 2017-10-25 | CuRNA, Inc. | Treatment of nuclear respiratory factor 1 (nrf1) related diseases by inhibition of natural antisense transcript to nrf1 |
| CA2785727C (en) | 2009-12-31 | 2020-01-07 | Curna, Inc. | Treatment of insulin receptor substrate 2 (irs2) related diseases by inhibition of natural antisense transcript to irs2 and transcription factor e3 (tfe3) |
| CA2785832A1 (en) | 2010-01-04 | 2011-07-07 | Curna, Inc. | Treatment of interferon regulatory factor 8 (irf8) related diseases by inhibition of natural antisense transcript to irf8 |
| KR101853509B1 (en) | 2010-01-06 | 2018-04-30 | 큐알엔에이, 인크. | Treatment of Pancreatic Developmental Gene Related Diseases By Inhibition of Natural Antisense Transcript to A Pancreatic Developmental Gene |
| JP6027893B2 (en) | 2010-01-11 | 2016-11-16 | カッパーアールエヌエー，インコーポレイテッド | Treatment of sex hormone binding globulin (SHBG) related diseases by inhibition of natural antisense transcripts against sex hormone binding globulin (SHBG) |
| EP2529015B1 (en) | 2010-01-25 | 2017-11-15 | CuRNA, Inc. | Treatment of rnase h1 related diseases by inhibition of natural antisense transcript to rnase h1 |
| CN102844435B (en) | 2010-02-22 | 2017-05-10 | 库尔纳公司 | Treatment of PYCR1-associated diseases by inhibiting the natural antisense transcript of pyrroline-5-carboxylate reductase 1 (PYCR1) |
| RU2612884C2 (en) | 2010-04-02 | 2017-03-13 | Курна, Инк. | Treatment of diseases associated with colonystimulating factor 3 (csf3) by inhibition of natural antisense transcript to csf3 |
| WO2011127337A2 (en) | 2010-04-09 | 2011-10-13 | Opko Curna Llc | Treatment of fibroblast growth factor 21 (fgf21) related diseases by inhibition of natural antisense transcript to fgf21 |
| WO2011139387A1 (en) | 2010-05-03 | 2011-11-10 | Opko Curna, Llc | Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt) |
| TWI531370B (en) | 2010-05-14 | 2016-05-01 | 可娜公司 | Treatment of PAR4-related diseases by inhibiting PAR4 natural anti-strand transcript |
| US8895528B2 (en) | 2010-05-26 | 2014-11-25 | Curna, Inc. | Treatment of atonal homolog 1 (ATOH1) related diseases by inhibition of natural antisense transcript to ATOH1 |
| ES2664585T3 (en) | 2010-05-26 | 2018-04-20 | Curna, Inc. | Treatment of diseases related to methionine sulfoxide reductase (MSRA) by inhibiting the natural antisense transcript to MSRA |
| CN109112126B (en) | 2010-06-23 | 2024-06-14 | 库尔纳公司 | Treatment of voltage-gated sodium channel alpha subunit (SCNA)-related diseases by inhibiting natural antisense transcripts of SCNA |
| JP5998131B2 (en) | 2010-07-14 | 2016-09-28 | カッパーアールエヌエー，インコーポレイテッド | DISCSLARGEHOMOLOG (DLG) Treatment of DLG-related diseases by inhibition of natural antisense transcripts on DLG1 |
| CN103210086B (en) | 2010-10-06 | 2017-06-09 | 库尔纳公司 | Treatment of NEU4-associated diseases by inhibiting the natural antisense transcript of sialidase 4 (NEU4) |
| KR101865433B1 (en) | 2010-10-22 | 2018-07-13 | 큐알엔에이, 인크. | Treatment of alpha-l-iduronidase (idua) related diseases by inhibition of natural antisense transcript to idua |
| US10000752B2 (en) | 2010-11-18 | 2018-06-19 | Curna, Inc. | Antagonat compositions and methods of use |
| WO2012071238A2 (en) | 2010-11-23 | 2012-05-31 | Opko Curna Llc | Treatment of nanog related diseases by inhibition of natural antisense transcript to nanog |
| KR102043422B1 (en) | 2011-06-09 | 2019-11-11 | 큐알엔에이, 인크. | Treatment of frataxin (fxn) related diseases by inhibition of natural antisense transcript to fxn |
| MX365525B (en) | 2011-09-06 | 2019-06-06 | Curna Inc | TREATMENT OF DISEASES RELATED TO ALPHA SUBUNITS OF SODIUM CHANNELS, VOLTAGE-GATED (SCNxA) WITH SMALL MOLECULES. |
| HK1210211A1 (en) | 2012-03-15 | 2016-04-15 | 科纳公司 | Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS62255499A (en) * | 1986-04-28 | 1987-11-07 | Teijin Ltd | Fluorescent nucleoside or nucleotide |
| WO1999006422A2 (en) * | 1997-07-31 | 1999-02-11 | Nycomed Amersham Plc | Base analogues |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5785048A (en) | 1980-11-17 | 1982-05-27 | Daicel Chem Ind Ltd | Exposed photosensitive diazo film for making screen plate |
| JPS6259293A (en) | 1985-09-09 | 1987-03-14 | Teijin Ltd | Fluorescent nucleoside or nucleotide |
| US5144019A (en) | 1989-06-21 | 1992-09-01 | City Of Hope | Ribozyme cleavage of HIV-I RNA |
| US5225337A (en) | 1989-09-25 | 1993-07-06 | Innovir Laboratories, Inc. | Ribozyme compositions and methods for use |
| US5840867A (en) | 1991-02-21 | 1998-11-24 | Gilead Sciences, Inc. | Aptamer analogs specific for biomolecules |
| US5582981A (en) * | 1991-08-14 | 1996-12-10 | Gilead Sciences, Inc. | Method for identifying an oligonucleotide aptamer specific for a target |
| US5756291A (en) * | 1992-08-21 | 1998-05-26 | Gilead Sciences, Inc. | Aptamers specific for biomolecules and methods of making |
| US6475998B1 (en) | 1997-03-06 | 2002-11-05 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Methods and compositions for the treatment of injury to the central nervous system |
| GB9708611D0 (en) | 1997-04-28 | 1997-06-18 | Univ Cardiff | Chemical compounds |
| US6127535A (en) | 1997-11-05 | 2000-10-03 | Ribozyme Pharmaceuticals, Inc. | Nucleoside triphosphates and their incorporation into oligonucleotides |
| US6458559B1 (en) * | 1998-04-22 | 2002-10-01 | Cornell Research Foundation, Inc. | Multivalent RNA aptamers and their expression in multicellular organisms |
| CA2330837C (en) | 1998-06-24 | 2008-11-18 | Chugai Seiyaku Kabushiki Kaisha | A vector expressing an rna viral full-length gene and its use |
| AU5723700A (en) | 1999-05-25 | 2000-12-12 | Praelux Incorporated | Method for sequency and characterizing polymeric biomolecules using aptamers anda method for producing aptamers |
| US6511809B2 (en) * | 2000-06-13 | 2003-01-28 | E. I. Du Pont De Nemours And Company | Method for the detection of an analyte by means of a nucleic acid reporter |
-
2003
- 2003-03-06 AU AU2003225701A patent/AU2003225701A1/en not_active Abandoned
- 2003-03-06 US US10/382,754 patent/US7144995B2/en not_active Expired - Lifetime
- 2003-03-06 WO PCT/US2003/006946 patent/WO2003077215A2/en not_active Ceased
- 2003-03-06 EP EP03744226A patent/EP1483280B1/en not_active Expired - Lifetime
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS62255499A (en) * | 1986-04-28 | 1987-11-07 | Teijin Ltd | Fluorescent nucleoside or nucleotide |
| WO1999006422A2 (en) * | 1997-07-31 | 1999-02-11 | Nycomed Amersham Plc | Base analogues |
Non-Patent Citations (4)
| Title |
|---|
| LIU C ET AL: "Fluorescence characterization of the transcription bubble in elongation complexes of T7 RNA polymerase", JOURNAL OF MOLECULAR BIOLOGY, LONDON, GB, vol. 308, no. 3, 4 May 2001 (2001-05-04), pages 465 - 475, XP004466086, ISSN: 0022-2836 * |
| LIU C ET AL: "Promoter Clearance by T7 RNA Polymerase", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOCHEMICAL BIOLOGISTS, BIRMINGHAM,, US, vol. 277, no. 4, 25 January 2002 (2002-01-25), pages 2725 - 2731, XP002981214, ISSN: 0021-9258 * |
| MCGUIGAN C ET AL: "ANTI-VARICELLA-ZOSTER VIRUS BICYCLIC NUCLEOSIDES: REPLACEMENT OF FURO BY PYRRO BASE REDUCES ANTIVIRAL POTENCY", ANTIVIRAL CHEMISTRY & CHEMOTHERAPY, BLACKWELL SCIENTIFIC PUBL., LONDON, GB, vol. 11, no. 5, September 2000 (2000-09-01), pages 343 - 348, XP001018124, ISSN: 0956-3202 * |
| See also references of WO03077215A2 * |
Also Published As
| Publication number | Publication date |
|---|---|
| EP1483280A2 (en) | 2004-12-08 |
| US7144995B2 (en) | 2006-12-05 |
| AU2003225701A8 (en) | 2003-09-22 |
| US20040009933A1 (en) | 2004-01-15 |
| AU2003225701A1 (en) | 2003-09-22 |
| EP1483280B1 (en) | 2012-10-24 |
| WO2003077215A3 (en) | 2004-07-01 |
| WO2003077215A2 (en) | 2003-09-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2003225701A8 (en) | Fluorescent nitrogenous base and nucleosides incorporating same | |
| EG24662A (en) | Purine compounds and uses thereof | |
| EP1539941A4 (en) | Adzymes and uses thereof | |
| AU2003278248A8 (en) | Diffusing substrate | |
| IL165588A0 (en) | Malonitrile compound and use thereof | |
| EP1540102A4 (en) | Tongue and groove panel | |
| EP1575495A4 (en) | Compounds and methods | |
| PL375355A1 (en) | Novel lipases and uses thereof | |
| GB0221513D0 (en) | Novel compounds and processes | |
| AU2003296369A8 (en) | Imminoamines and preparation thereof | |
| GB0220385D0 (en) | Compound and process | |
| IL165112A0 (en) | Variant integrinpolypeptides and thereof | |
| AU2003227404A8 (en) | Discharge light and back light | |
| GB0221438D0 (en) | Processes and compounds | |
| AU2003231827A8 (en) | Pseudo-tissues and uses thereof | |
| AU2003224912A8 (en) | Dyes and fluorescent compounds | |
| AU2003302173A8 (en) | Spirotetrathiocarbamates and spirooxothiocarbamates | |
| AU2003215379A1 (en) | Substituted pyrimidinones and pyrimidinthiones | |
| GB0204836D0 (en) | Lamp monitor and lamp | |
| ZA200500870B (en) | Support and guide | |
| GB0207624D0 (en) | Chemokine and uses thereof | |
| AU2003228397A8 (en) | Hausp-p53 interaction and uses thereof | |
| GB0227876D0 (en) | Process and supports | |
| AU2003216442A8 (en) | Enkurin and uses thereof | |
| AU2003282583A8 (en) | Via-less electronic structures and methods |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 20040920 |
|
| AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR |
|
| AX | Request for extension of the european patent |
Extension state: AL LT LV MK |
|
| A4 | Supplementary search report drawn up and despatched |
Effective date: 20070402 |
|
| 17Q | First examination report despatched |
Effective date: 20081222 |
|
| GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
| GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
| GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
| AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR |
|
| AX | Request for extension of the european patent |
Extension state: AL LT LV MK |
|
| REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
| REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
| REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 580892 Country of ref document: AT Kind code of ref document: T Effective date: 20121115 |
|
| REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
| REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 60342429 Country of ref document: DE Effective date: 20121220 |
|
| REG | Reference to a national code |
Ref country code: CH Ref legal event code: NV Representative=s name: SCHNEIDER FELDMANN AG PATENT- UND MARKENANWAEL, CH |
|
| REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 580892 Country of ref document: AT Kind code of ref document: T Effective date: 20121024 |
|
| REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG9D |
|
| REG | Reference to a national code |
Ref country code: NL Ref legal event code: VDEP Effective date: 20121024 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20121024 Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20121024 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20121024 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20121024 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20130125 Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20121024 Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20121024 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20130225 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20121024 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20121024 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20121024 Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20130124 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20121024 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20121024 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20121024 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20121024 |
|
| PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
| 26N | No opposition filed |
Effective date: 20130725 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20130204 Ref country code: MC Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20130331 |
|
| REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 60342429 Country of ref document: DE Effective date: 20130725 |
|
| REG | Reference to a national code |
Ref country code: IE Ref legal event code: MM4A |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20130306 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20121024 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20130306 Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20030306 |
|
| REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 14 |
|
| REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 15 |
|
| REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 16 |
|
| REG | Reference to a national code |
Ref country code: CH Ref legal event code: PFA Owner name: GLEN RESEARCH CORPORATION, US Free format text: FORMER OWNER: GLEN RESEARCH CORPORATION, US |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20220328 Year of fee payment: 20 Ref country code: DE Payment date: 20220329 Year of fee payment: 20 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20220325 Year of fee payment: 20 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CH Payment date: 20220404 Year of fee payment: 20 |
|
| REG | Reference to a national code |
Ref country code: DE Ref legal event code: R071 Ref document number: 60342429 Country of ref document: DE |
|
| REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
| REG | Reference to a national code |
Ref country code: GB Ref legal event code: PE20 Expiry date: 20230305 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20230305 |